Pressreleaser | 20 Oct 2022 | Scandinavian Chemotech

Scandinavian ChemoTech AB publishes supplementary prospectus

Scandinavian ChemoTech AB (publ) (”ChemoTech” or the ”Company”) has established a supplement (the ”Supplementary Prospectus”) in addition to the EU growth prospectus regarding subscription of units in the ongoing rights issue (the ”Rights Issue”) that was approved and published on September 29, 2022 (the ”Prospectus”). The Supplementary Prospectus is part of, and shall be read together with, the Prospectus.

The Supplementary Prospectus has been prepared as ChemoTech, after publication of the Prospectus, announced through press releases on October 18, 2022, that (i) the Company’s Animal Care-division Vetiqure AB has entered a distribution agreement for the Australian and New Zeeland veterinary market with Gamma Gurus Pty Ltd, and (ii) signed a Letter of Intent regarding a distribution agreement for the North American veterinary market with Avante Animal Health. The press releases are available on the Company’s website, www.chemotech.se.

Investors who, prior to the publication of this Supplementary Prospectus, have made a subscription or otherwise agreed to subscribe for units in the Rights Issue are entitled under Article 23 of Regulation (EU) 2017/1129 to withdraw their subscription or consent within three working days of the publication of the Supplementary Prospectus, i.e., until October 25, 2022. Withdrawal must be made via e-mail to emissioner@mangold.se.Investors who have subscribed for units in the Rights Issue through a nominee must contact their nominee for withdrawal. Subscriptions that have not been withdrawn within the specified time will remain binding and investors who wish to remain with their subscription for units in the rights issue do not need to take any action.

The Prospectus and the Supplementary Prospectus are available on www.chemotech.se. For terms and conditions and other information about the Rights Issue, please refer to the Prospectus.

For more information, please contact:

Mohan Frick, CEO

Tel: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel:+46 8-463 80 00, E-mail:certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech’s shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company’s Certified Adviser. Read more at: www.chemotech.se.

Important Information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subjectto restrictions according to law and people in those jurisdictions, in which this press release has beenannounced or distributed, should inform themselves of and follow such legal restrictions. This pressrelease does not constitute an offer, or a solicitation of any offer, to buy or subscribe for anysecurities in ChemoTech in any jurisdiction. Invitation to the persons concerned to participate in the RightsIssue will only take place through the EU growth prospectus which the Company intends to publishin connection with the Rights Issue.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribefor securities in the United States. The securities referred to herein may not be sold in the UnitedStates absent registration or an exemption from registration under the US Securities Act of 1933, asamended. The information in this press release may not be announced, published or distributed, directly or indirectly, in whole or in part, inor into the United States, Australia, Hong Kong, Japan, Canada, New Zealand,Switzerland, South Africa, South Korea or in any other jurisdiction where the announcement, publication ordistribution of the information would not comply with applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country otherthan Sweden. In other Member States of the European Union, such an offer may  only be made inaccordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.

This press release contains certain forward-looking information that reflects the Company’s presentview of future events as well as financial and operational development. Words such as ”intend”,”assess”, ”expect”, ”may”, ”plan”, ”believe”, ”estimate” and other expressions entailing indicationsor predictions of future development or trends, not based on historical facts, constitute forward-lookinginformation. Forward-looking information is inherently associated with both known andunknown risks and uncertainties as it depends on future events and circumstances. Forward-lookinginformation is not a guarantee of future results or development and actual outcomes may differmaterially from the statements set forth in the forward-looking information.